[유기화학기술] SHIONOGI & CO., Ltd./ Shionogi, Inc. 대 Aurobindo Pharma Ltd./ AUROBINDO PHARMA U.S.A., Inc. 간의 유기화학기술 관련 특허 분쟁
발생일자 2015.01.16
사건번호 1:15-cv-00478
법원국가 UNITED STATES OF AMERICA
관할법원명 D.C.N.D.Illinois(지방법원)
침해권리 특허
원고명 SHIONOGI & CO., Ltd./ Shionogi, Inc. ( 일본 / 외국기업 )
피고명 Aurobindo Pharma Ltd./ AUROBINDO PHARMA U.S.A., Inc. ( 인도 / 외국기업 )
소송유형 침해금지
분쟁내용
[SHIONOGI & CO., Ltd. et al v. Aurobindo Pharma Ltd. et al] 사건번호 1:15-cv-00478에 따르면 원고 SHIONOGI & CO., Ltd./ Shionogi, Inc.는 피고 Aurobindo Pharma Ltd./ AUROBINDO PHARMA U.S.A., Inc.을 상대로 특허 US8247402 을 침해하였다는 이유로 미국 일리노이 북부 지방법원에 소를 제기하였다.
분쟁결과 분쟁중
산업분류 화학∙바이오 > 유기화학기술
계쟁제품 Generic doripenem for injection products, generic copies of Shionogi's
지재권번호/명칭
US8247402 Crystal form of pyrrolidylthiocarbapenem derivative
Crystal form of pyrrolidylthiocarbapenem derivative
Abstract
Novel crystals of a pyrrolidylthiocarbapenem derivative having excellent stability is provided. According to the present invention, a crystal of (+)-(4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3[[(3S,5S)-5-(sulfa- moylaminomethyl)p yrrolidin-3-yl]thio]-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid having a diffraction pattern in powder X-ray diffraction having main peaks at diffraction angles (2.theta.) of about 13.04, 14.98, 15.88, 16.62, 20.62, 21.06, 22.18, 23.90, 26.08, 28.22 and 28.98 (degrees) and a crystal of said compound having a diffraction pattern in powder X-ray diffraction having main peaks at diffraction angles (2.theta.) of about 6.62, 13.04, 15.44, 16.58, 17.64, 20.88, 23.26, 25.02 and 25.52 (degrees) are provided.
Claims
The invention claimed is:
1. A crystal of a monohydrate of (+)-(4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3[[(3S,5S)-5-(sulfa- moylaminomethyl)pyrrolidin-3-yl]thio]-1-azabicyclo[3.2.0]hept-2-ene-2-carb- oxylic acid, said crystal having a powder X-ray diffraction pattern comprising peaks at diffraction angles (2.theta.) of about 13.04, 14.98, 15.88, 16.62, 20.62, 21.06, 22.18, 23.90, 26.08, 28.22 and 28.98 (degrees), wherein the powder X-ray diffraction pattern is obtainable using Cu K.alpha. ray, 1.34 Angstroms (monochromator), tube voltage 40 kV, and tube current 40 mA.
2. A medicament comprising a crystal of a monohydrate of (+)-(4R,5S,6S)-6-[1R)-1-hydroxyethyl]-4-methyl-7-oxo-3 [[(3S,5S)-5-(sulfamoylaminomethyl) pyrrolidin-3-yl]thio]-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid in a solid form, said crystal having a powder X-ray diffraction pattern comprising peaks at diffraction angles (2.theta.) of about 13.04, 14.98, 15.88, 16.62, 20.62, 21.06, 22.18, 23.90, 26.08, 28.22 and 28.98 (degrees), wherein the powder X-ray diffraction pattern is obtainable using Cu K.alpha. ray, 1.34 Angstroms (monochromator), tube voltage 40 kV, and tube current 40 mA; and one or more pharmaceutically acceptable ingredients.
3. A medicament according to claim 2, wherein the medicament is a powder filling preparation.
4. A method for producing a crystal according to claim 1, comprising the steps of: (A) dissolving (+)-(4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3 [[(3S,5S)-5-(sulfamoylaminomethyl)pyrrolidin-3-yl]thio]-1azabicyclo[3.2.0- ]hept-2-ene-2-carboxylic acid or a hydrate thereof in water; (B) depositing crystals from the aqueous solution obtained in step (A); (C) determining the powder X-ray diffraction pattern of the crystals; (D) selecting a crystal having a powder X-ray diffraction pattern comprising peaks at diffraction angles (2.theta.) of about 6.62, 13.04, 15.44, 16.58, 17.64, 20.88, 23.26, 25.02 and 25.52 (degrees), wherein the powder X-ray diffraction pattern is obtainable using Cu K.alpha. ray, 1.34 Angstroms (monochromator), tube voltage 40 kV, and tube current 40 mA; and (E) drying the crystal obtained in step (D).
5. A method for preparing an injectable solution comprising the step of dissolving the crystal according to claim 1, or a medicament according to claim 2, in a physiologically acceptable agent.